Chinese genetic sequencing firm Novogene ​sued the Pentagon ‌late Tuesday in U.S. District Court in ​Washington over its ​inclusion on a US ⁠list of ​companies allegedly aiding Beijing's ​military.

Nov 4 : Chinese genetic sequencing firm Novogene sued the ​Pentagon late Tuesday in U.S. District Court in Washington over its inclusion on a US list of companies allegedly ‌aiding Beijing's military.In June, the Defense Department added Novogene, Chinese e-commerce giant Alibaba internet search provider

Chinese genetic sequencing firm Novogene ​sued the Pentagon ‌late Tuesday in U.S. District Court in ​Washington over its ​inclusion on a US ⁠list of ​companies allegedly aiding Beijing's ​military.

Chinese genetic sequencing firm Novogene sued the Pentagon late Tuesday in US District Court in Washington over ​its inclusion on a US list of companies allegedly aiding Beijing's military.

Source: CNA

The 2026 Sponsors of the Human Cell Atlas Asia Meeting.

In this interview, News Medical-Life Sciences speaks with Dr. Shi-Qi An, Director of Marketing and Science Communications at Novogene Europe, about the growing importance of omics technologies in modern biological research. Drawing on her background in molecular microbiology, antimicrobial research and genomics, Dr. An discusses how integrating different omics approaches can uncover complex biological mechanisms, improve experimental design and support drug discovery. Image credit: jittawit21/Shutterstock.com Can you please introduce yourself and explain how your background in molecular microbiology has shaped your work at Novogene Europe? My background is originally in molecular microbiology, and I spent many years working in academic research. During that time, I worked in fundamental science, using different technologies, from genomics and transcriptomics through to structural biology, to understand microbial systems and infection models. Later in my academic career, I moved towards more translational research, particularly antimicrobial target identification and drug discovery. This involved investigating potential therapeutic targets and developing different experimental models to test candidate compounds. That experience helped me transition from academic research to industry. I discovered that my strength lies in connecting science to practical, commercial applications. In a life sciences company, it is important not only to understand the technology itself but also...

The authors want to thank Yuemao Shen for helpful discussions, Shu’e Wang, Wenwen Zheng, Ruirui Kou, Cuiqin Zhang, Xiaomin Ma, and Qi Han for their assistance in experiments, the Genechem Co., Ltd. (Shanghai, China) for single-cell RNA sequencing, Novogene Co. Ltd. (Beijing, China) for TMT proteomics sequencing, and the scientific drawing platform BioRender. The licenses for the previously created elements in BioRender received by S.W. (2026): IK2A36JKOQ https://BioRender.com/fyw2hdg, LC2A36FN5R https://BioRender.com/obmqz8q, RB2A36EYNJ https://BioRender.com/vvzcfke, and OE2A36PYP5 https://BioRender.com/ruy33ac. This study was mainly supported by National Natural Science Foundation of China (82304176), General Program of Guangdong Natural Science Foundation (2026A1515011526), Guangzhou Science and Technology Plan Project (2024A04J3307, 2024A04J5139), General Project of Shandong Natural Science Foundation (ZR2021MC166), a Grant (K22-2056) from International Joint Usage/Research Center, the Institute of Medical Science, the University of Tokyo (IMSUT), a Grant (6-16) from Joint Research Program of the Institute for Genetic Medicine (IGM), Hokkaido University, and a Postdoctoral Fellowship for Research in Japan (P26106) of Japan Society for the Promotion of Science (JSPS). This study was also partly supported by Program for Changjiang Scholars and Innovative Research Team in University (IRT_17R68). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial...